# A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer

Source: https://onco.cc/trials/nct06151262/  
OnCo record `nct06151262` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, now recruiting.

## Summary

A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer is a phase 2, interventional study registered as NCT06151262 by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, with a registry enrolment figure of 30 participants, started 2024-01-20 and due to reach its primary completion in 2025-05-28. Interventions recorded: Trilaciclib+mFOLFIRINOX. Conditions listed: Pancreatic Cancer. Primary outcome: Incidence of CIM. Pancreatic eligibility wording from the registry: "* Patients with histologically or cytologically confirmed pancreatic cancer". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06151262
- Phase: 2
- Setting: A Single-arm, Exploratory Clinical Study of Trilaciclib Combined With mFOLFIRINOX Regimen in the Treatment of Patients With Advanced Pancreatic Cancer
- Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06151262: https://clinicaltrials.gov/study/NCT06151262

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06151262.json